Amgen's Tezspire achieves sustained remission in Phase 3 eosinophilic esophagitis trial
AMGN•Amgen and AstraZeneca said Tezspire improved swallowing symptoms and tissue inflammation versus placebo in the Phase 3 CROSSING trial, with benefits sustained through one year. More treated patients achieved complete endoscopic remission; eosinophilic esophagitis remains an investigational use.
1. Trial results
Amgen and AstraZeneca announced positive Phase 3 CROSSING results for Tezspire in adolescents and adults with uncontrolled eosinophilic esophagitis. The drug improved swallowing symptoms and tissue inflammation versus placebo, with benefits sustained through one year, and more treated patients achieved complete endoscopic remission. The safety profile was consistent with existing indications. Results are scheduled to be presented at United European Gastroenterology Week 2026 in Barcelona.
